XOMA Cancer Drugs Clinical Pipeline Insight

Reports
Published
Number of pages
33

For Wire/Bank transfer, contact us at info@pnspharma.com

Electronic Access - Single User License
$500
CD-ROM Mail Delivery
$800
Hard Copy Mail Delivery
$800
Electronic Access - Multi-User License
$1000

“XOMA - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by XOMA. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “2” cancer drugs in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“XOMA - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Xoma

  1.1 Business Overview

  1.2 Xoma Cancer Pipeline Overview

 

2. XOMA Cancer Drugs in Preclinical Phase

  2.1 Antineoplastic Antibodies - Monopar Therapeutics

 

3. XOMA Cancer Drugs in Phase-II

  3.1 Ficlatuzumab

 

4. No Development Reported in Cancer Drugs in Clinical Pipeline

  4.1 Gevokizumab

  4.2 Angiogenesis Inhibitors – XOMA

 

5. Discontinued in Cancer Drugs in Clinical Pipeline

  5.1 XOMA 213

  5.2 Gevokizumab

  5.3 Lucatumumab

  5.4 Anti-Transforming Growth Factor Beta Antibodies- XOMA Corporation/Novartis

  5.5 Therapeutic Monoclonal Antibodies - Takeda/XOMA

  5.6 Anti-Gastrin Antibodies – XOMA

  5.7 T Lymphocyte-Targeted Immunofusion Protein

  5.8 XomaZyme-Mel

  5.9 Monoclonal Antibody-Ricin-Chain-A Conjugate

  5.10 XomaZyme-791

Figure 1-1: Xoma Cancer Pipeline by Phase (%)

Figure 1-2: Xoma Cancer Pipeline by Phase (Number)

Figure 1-3: Xoma Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Xoma Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)